Medical Developments International Limited (ASX: MVP) is delighted to announce it has received Marketing Authorisation for Penthrox in France for the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.
MVP CEO, Mr John Sharman, said: “This is an exciting achievement for MVP. With French approval we can begin to sell product in France and Belgium. Preparations for the launch of Penthrox in France and Belgium are well advanced.”
Mr Sharman said: “The approval in France is another step towards selling Penthrox into key global markets around the world. The approval triggers another milestone payment of $USD 3.0 million from Mundipharma, our partner in Europe.”
Kate Hurtig, Head of Pain at Mundipharma International added: “Mundipharma has a proud heritage in pain management and is committed to advancing important new therapeutics in this space. We are excited about the opportunity to begin to sell Penthrox in Europe and the prospect for growth which that brings.”
The Chairman of MVP, David Williams, said: “French approval is a red-letter day for MVP, not because we can now sell in France, but because it also signals the start of our quest for the approval in 28 other countries in the EU that we will seek as part of the Decentralised Approval process”.
About Penthrox
Penthrox is a fast onset, non-opioid analgesic which is indicated in Australia for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 30 years in Australia with excess of 5 million units sold. Mundipharma International has exclusive product rights in 39 European markets (including France, Germany, Italy and Spain, but excluding Hungary, Republic of Ireland and the United Kingdom).
About Medical Developments International Ltd
MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.
About Mundipharma
The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world’s pharmaceutical markets. These companies are committed to bringing to patients the benefits of pioneering treatment options in the core therapy areas of pain management, oncology, respiratory and inflammatory conditions. Through innovation, design and acquisition, the Mundipharma network of independent associated companies delivers important treatments to meet the most pressing needs of patients, healthcare professionals and health systems worldwide.
